林业发展局核准IV tocilizumab-anoh治疗成人、儿童严重免疫反应。 FDA approves IV tocilizumab-anoh for treating severe immune reactions in adults, children.

美国食品和药物管理局批准了托西利祖马布- 安诺 (AVTOZMA) 的静脉注射形式,这是托西利祖马布 (Actemra) 的生物类似药,用于治疗2岁或以上的成人和儿童的严重细胞因子释放综合征 (CRS). The FDA has approved the IV form of tocilizumab-anoh (AVTOZMA), a biosimilar to tocilizumab (Actemra), to treat severe cytokine release syndrome (CRS) in adults and children aged 2 or older. CRS是过度活跃的免疫反应引起的一种危险状况。 CRS is a dangerous condition caused by an overactive immune response. 此项核准使AVTOZMA的表示与Actemra的表示相一致,包括风湿性关节炎和COVID-19的治疗。 This approval aligns AVTOZMA's indications with those of Actemra, including treatments for rheumatoid arthritis and COVID-19. 从2025年8月31日起,AVTOZMA将在美国提供。 AVTOZMA will be available in the US starting August 31, 2025.